Global Health Impact Programs

Good quality medicines are essential to survival, and providing sustainable access to them is imperative. Through its four Global Health Impact Programs (GHIP), the United States Pharmacopeial Convention (USP) strives to help under-resourced countries combat substandard and counterfeit medicines by building local capacity (i.e., systems, training, infrastructure, and networks) so that they can effectively monitor, test, and regulate the quality of medicines available in their communities.

GHIP programs offer a variety of opportunities—education, outreach, standards resources, consulting—to help regional governments, regulators, and manufacturers implement systemic medicine quality control improvements and foster collaborations that can function without outside assistance. By promoting self-sustainable, localized change, USP hopes to meet its ultimate goal, which is to eliminate the need for GHIP to exist.

Visit the links below to learn about the four GHIP programs and the progress they have made:

• Promoting the Quality of Medicines (PQM)
• Technical Assistance Program (TAP)
• Official Medicines Control Laboratory (OMCL) Networks
• Center for Pharmaceutical Advancement and Training (CePAT)